

Randomised Evaluation of COVID-19 Therapy: the RECOVERY trial

Collaborators' Meeting

26th October 2020





- 1. Introductions
- 2. Update on progress
- 3. REGN-COV2
- 4. Tocilizumab
- 5. Other developments
- 6. Trial procedures
- 7. Pregnancy update
- 8. Q&A

Introductions




- One of the central study team will talk to the agenda
- If you have questions please enter them into the "Q&A" on the right side of your screen.
- Questions may be answered directly or to the whole group



PROGRESS UPDATE


Current trial design





Recruitment by site and by time









Tocilizumab vs control

 Convalescent plasma vs REGN-COV2 vs control








- As local outbreaks occur, please consider discussing with your teams how to ensure that all available admissions with Covid-19 are identified and enrolled if possible
 - Daily catch-up with admitting teams
 - Links with laboratory for all positive swabs among patients to be reported
- Average recruitment remains at about 12% of all COVID-19 admissions, but with significant variation between sites







- Pilot of additional funding for weekend working in November
- Potential adoption onto NIHR Associate PI scheme (more details will follow)




REGN-COV2

REGN-COV2



• REGN-COV2 is a mixture of two monoclonal antibodies (mAbs: REGN10933 and REGN10987)



- These are fully human antibodies directed against spike protein
- Two different antibodies mean that if virus mutates its spike protein such that one antibody doesn't bind so well, the other antibody probably still will

REGN-COV2 site setup



- 1. Local PIs need to complete online training and confirmation form
 - They should ask other staff involved at site to also do this, but not require before site activation
- 2. Pharmacy need to be ready to support new arm
 - Review Pharmacy Manual on website and complete local risk assessment to determine where mAb will be prepared
 - Confirm staff details to RECOVERY team
 - Indicate when they will be ready to:
 - 1. Receive drug
 - 2. Support allocation to a trial participant

REGN-COV2 dos and don'ts



 Please DO NOT indicate REGN-COV2 is available if system suggests it is not unless you are absolutely sure!

Are the following treatments available?

A15.1 Azithromycin	~
A15B.1 Convalescent plasma	~
A15B.2 Synthetic monoclonal antibodies (REGN10933+REGN10987) Please check with your PI before changing	No 🛩

• Please don't ignore the warning!

A15B.2 Synthetic monoclonal antibodies (REGN10933+REGN10987) Please check with your PI before changing Please ensure this treatment is definitely available before continuing



Otherwise the participant may be allocated a treatment they can't have ⁽³⁾

When to include REGN-COV2



- REGN-COV2 should be administered as soon after randomisation as possible
- If being prepared in pharmacy, this may not be until next working day
- If delay is likely to be longer (e.g. at weekend), please indicate that mAb is <u>unavailable</u> on randomisation form so it will not be allocated



TOCILIZUMAB

Tocilizumab



• Several recent publications

Trial name	Number of participants	Number of deaths	HR (95% CI)	
RCT-TCZ-COVID-19	126	4	2.1 (0.2-22.6)	
CORIMUNO-19	131	15	0.92 (0.33-2.53)	
BACC	243	12	1.52 (0.41-5.61)	
COVACTA	438	86	1.02 (0.62-1.68)*	* Estimated from published
ΕΜΡΑCΤΑ	389	~37*	not estimable	data

• JAMA editorialist: "I plan to wait out the torrent of positive observational studies and reconsider tocilizumab's use in COVID-19 if, and only if, more compelling data from randomized trials emerges."

Tocilizumab



- Nearly 1300 randomised
- Sufficient tocilizumab supply for 4000 randomised, but all now at sites
- Please ensure you consider this randomisation for appropriate participants:
 - On oxygen (or sats <92%)
 - CRP ≥75 mg/L



OTHER DEVELOPMENTS

CTAP



Department of Health & Social Care

Guidance: making a proposal for COVID-19 therapeutics clinical trials

Published 17 August 2020

Contents

Introduction UK COVID-19 Therapeutics Advisory Panel (UK-CTAP) UK-CTAP Membership Proposal process for COVID-19 treatments Additional information

Introduction

Given the success of the Phase III RECOVERY platform in delivering a single platform trial across the NHS, the UK Government has increased investment in an expanded platform which will operate for the next 24 months. This will include new treatments tested in Phase II and Phase III studies which will now be delivered through the RECOVERY platform (RECOVERY+) in patients admitted to hospital.

New treatments can be proposed for inclusion in the RECOVERY+ platform for both Phase II and Phase III trials. They will be considered by the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP).

Subcommittees that have met to date:

- Antiviral
- Anticoagulation
- Immunomodulation
- Renin-angiotensin system

• One recommendation from CTAP is being discussed with manufacturer

• Outcome from anticoagulation subcommittee imminent

Pharmacogenomic substudy




- Azithromycin known to prolong QT interval, but genetic determinants unknown
- Substudy for interested sites which requires:
 - ECG prior at baseline and 48h (uploaded to OpenClinica)
 - Co-enrolment into GenoMICC or ISARIC-4C encouraged (for genetic samples)
- Please e-mail <u>recoverytrial@ndph.ox.ac.uk</u> if interested

SOLIDARITY



• 11,266 participants randomised in 30 countries





TRIAL PROCEDURES

Serum samples




- All participants entering antibody comparison (CP vs mAb vs control) need to have serum sample collected prior to randomisation
- Can be taken with G&S sample after consent prior to randomisation to limit venepunctures
- Must be taken for all participants in that comparison (regardless of allocation)

Completeness of follow-up



- Weekly reminders highlighting participants randomised >28 days ago without complete form and also those needing an Antibody Comparison 72h safety form
- Please do complete these as soon as possible



Follow-up form completion summary

Carry on recruiting!



- RECOVERY remains the largest global trial in COVID-19 and is an exemplar of what trials can do (both in and after pandemic)
- Current therapies are exciting, but need reliable data before they should be used routinely
- Thank you for your support!



Randomised Evaluation of COVID-19 Therapy: the RECOVERY trial

Collaborators' Meeting for Pregnancy

26 October 2020

RECOVERY for pregnant women



- 1. Update on covid-19 and pregnancy
- 2. Update on adaptions
- 3. Update on UKOSS
- 4. Future plans
- 5. Q&A

Covid-19 and pregnancy

RECXVERY Randomised Evaluation of COVID-19 Therapy

RESEARCH

Clinical manifestations, risk factors, and maternal and perinatal OPEN ACCESS Characteristics and outcomes of pregnant women admitted to outcomes of coronavirus disease 2019 in pregnancy: living Check for updates systematic review and meta-analysis hospital with confirmed SARS-CoV-2 infection in UK: national Check for updates FAST TRACK BMJ: John Allotey, ^{1,2} Elena Stallings, ^{3,4} Mercedes Bonet, ⁵ Magnus Yap, ⁶ Shaunak Chatterjee, ⁶ population based cohort study Tania Kew,⁶ Luke Debenham,⁶ Anna Clavé Llavall,⁶ Anushka Dixit,⁶ Dengyi Zhou,⁶ Rishab Balaji,⁶ Siang Ing Lee,¹ Xiu Qiu,^{7,8,9} Mingyang Yuan,^{1,7} Dyuti Coomar,¹ Madelon van Wely,¹⁰ Marian Knight,¹ Kathryn Bunch,¹ Nicola Vousden,² Edward Morris,³ Nigel Simpson,⁴ Chris Gale,⁵ Elizabeth van Leeuwen,¹¹ Elena Kostova,¹⁰ Heinke Kunst,^{12,13} Asma Khalil,¹⁴ Simon Tiberi,^{12,13} Patrick O'Brien,⁶ Maria Quigley,¹ Peter Brocklehurst,⁷ Jennifer J Kurinczuk,¹ On behalf of the UK Vanessa Brizuela,⁵ Nathalie Broutet,⁵ Edna Kara,³ Caron Rahn Kim,⁵ Anna Thorson,⁵ Obstetric Surveillance System SARS-CoV-2 Infection in Pregnancy Collaborative Group Olufemi T Oladapo,⁵ Lynne Mofenson,¹⁵ Javier Zamora,^{3,4,16} Shakila Thangaratinam,^{2,17} for PregCOV-19 Living Systematic Review Consortium For numbered affiliations see ABSTRACT over, and 145 (34%) had pre-existing comorbidities. For numbered affiliations see ABSTRACT meta-analysis was performed, with estimates pooled end of the article. **OBIECTIVES** 266 (62%) women gave birth or had a pregnancy loss; end of the article OBIECTIVE as odds ratios and proportions with 95% confidence Correspondence to: M Knight To describe a national cohort of pregnant women 196 (73%) gave birth at term. Forty one (10%) women Correspondence to: To determine the clinical manifestations, risk factors, intervals. All analyses will be updated regularly. marian.knight@npeu.ox.ac.uk S Thangaratinam and maternal and perinatal outcomes in pregnant and admitted to hospital with severe acute respiratory admitted to hospital needed respiratory support, and RESULTS (or @Marianfknight and @NPEU_ s.thangaratinam.1@bham.ac.uk recently pregnant women with suspected or confirmed UKOSS on Twitter: syndrome coronavirus 2 (SARS-CoV-2) infection in five (1%) women died. Twelve (5%) of 265 infants (or @thangaratinam on Twitter: 77 studies were included. Overall, 10% (95% ORCID 0000-0002-4254-460X) coronavirus disease 2019 (covid-19). ORCID 0000-0002-1984-4575) confidence interval 7% to14%: 28 studies, 11432 the UK, identify factors associated with infection, tested positive for SARS-CoV-2 RNA, six of them within Additional material is published DESIGN man) of prognant and recently prognant Additional material is published and describ ase visit Livin online only. To view please visit infection, fo **EDITORIALS** the journal online. 70:m3320 DAT/ Maternal, Newborn and Cite this as: BM/2020:369:m2107 DESIGN omj.m3320 Med data Check for updates http://dx.doi.org/10.1136 bmi.m2107 Prospective Infant Clinical Outcome Mothers and Babies: Reducing Risk through (CNK using the UI Audits and Confidential Enguiries across the UK Accepted: 27 May 2020 201 Include pregnant women in research—particularly covid-19 research **Review Programme** SETTING socia National Perinatal Epidemiology Unit Nuffield Department of Population All 194 obst Health, University of Oxford, Oxford, Adapting interventions and changing attitudes will drive scientific progress Marian Knight, ¹ R Katie Morris, ² Jenny Furniss, ³ Lucy C Chappell⁴ ² Institute of Applied Health Research, University of Birmingham, The UK Confidential Enquiries into Maternal Deaths or breastfeeding allows safety concerns to be allayed Birmingham, UK have repeatedly highlighted inequities in the medical for women, their families, and healthcare Saving Lives, Improving Mothers' Care ³ UK Obstetric Surveillance System treatment of pregnant and postpartum women, noting professionals. Steering Committee, National that women are denied investigations and life Even if regulatory barriers have been overcome, Perinatal Epidemiology Unit, Oxford, preserving treatments simply because they are gatekeeping or inertia may occur if local ethics pregnant or breastfeeding.12 These inquiries committees take an overwhelming precautionary ⁴ School of Life Course Sciences, King's emphasise that the default position should be to Rapid report: Learning from SARS-CoV-2-related approach, overriding recognition of the potential College London, London, London, Ul investigate and treat pregnant and breastfeeding benefits of including pregnant and breastfeeding Correspondence to: L C Chappell women in the same way as non-pregnant women. women. This problem can be mitigated by a strong and associated maternal deaths in the UK lucy.chappell@kcl.ac.uk unless there are clear reasons not to.¹ network of maternity researchers, familiar with Cite this as: BMJ 2020;370:m3305 Clinical trials, particularly those of drug treatments, delivering drug trials in pregnancy, who can be http://dx.doi.org/10.1136/bmj.m3305 have typically automatically excluded pregnant or rapidly mobilised to help implement studies.

Published: 25 August 2020

breastfeeding women meaning data are unavailable

RESEARCH

Covid-19 and pregnancy



Headline messages:

- Covid-19 affects pregnant women
- Additional risk factors identified
- Pregnant and postnatal women need evidence-based treatments
- Actively include pregnant and postnatal women in research
- RECOVERY trial has changed clinical practice, including for pregnant women

Covid-19 and pregnancy: RCOG





Royal College of Obstetricians & Gynaecologists

Coronavirus (COVID-19) Infection in Pregnancy The in

Information for healthcare professionals

Version 12: Published Wednesday 14 October 2020

The interim results of the RECOVERY trial demonstrated a significant reduction in 28-day mortality for individuals with COVID-19 requiring oxygen who were given steroid therapy (age-adjusted rate ratio 0.83; 95% CI 0.75–0.93; P<0.001),¹⁰³ and this has been recommended for use in the NHS.¹⁰⁴ The RECOVERY trial protocol for pregnancy recommends prednisolone 40 mg orally once daily, and, in women unable to take oral medicine, hydrocortisone 80 mg intravenously twice daily instead of dexamethasone treatment.^{16 105 106}

Remdesivir is currently subject to a therapeutic alert for pregnancy; it should be avoided unless benefits outweigh risks, following multidisciplinary discussion.¹⁰⁷ Remdesivir is an antiviral medication which has been shown to be associated with a reduction in time to clinical improvement in individuals with severe COVID-19, median 11 versus 15 days, rate ratio 1.32 (95% Cl 1.12–1.55).¹⁰⁸

Pregnant women can be enrolled in the RECOVERY trial.

Where therapies or participation in trials are offered, they should also be considered for and offered to pregnant women.

RECOVERY for pregnant women





♠ / For Site Staff / site teams

Site teams

This page contains additional information for RECOVERY site team members. Follow these links for guidance on randomisation and how to collect follow-up data.

RECOVERY Privacy Notice for Trial Staff

INTERVENTION INFORMATION

RECOVERY intervention sheet - dexamethasone (now only recruiting children)

RECOVERY intervention sheet - azithromycin

RECOVERY intervention sheet - tocilizumab

RECOVERY intervention sheet - assessing patients for risk of transfusion associated circulatory overload (TACO) prior to convalescent plasma transfusions

RECOVERY Laboratory Standard Operating Procedure (SOP) v2

REGN-COV2 administration quick reference guide

Arrhythmia sub study user guide

GUIDES FOR SPECIFIC PATIENT	COLLABORATORS' MEETINGS SLIDES
GROUPS	We apologise if you were unable to join the meetings.
RECOVERY for paediatric patients	6 October 2020
RECOVERY for patients with chronic kidney	5 October 2020
disease	14 & 15 September 2020
RECOVERY for pregnant and breastfeeding women	3 & 4 August 2020
RECOVERY and remdesivir	14 July 2020
	13 July 2020
	30 June 2020
	29 June 2020
	16 June 2020
	15 June 2020

Pregnancy information document

RECXVERY

Randomised Evaluation of COVID-19 Therapy

RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)

for pregnant and breastfeeding women Pregnancy leads: Prof Lucy Chappell, Prof Marian Knight

	RECOVERY trial protocol	Adaption for pregnancy
Eligibility	Patients are eligible if all of the following are true:	Same eligibility
	i. Hospitalised	
	ii. SARS-CoV-2 infection	
	iii. No medical history that might, in the opinion of the	
	attending clinician, put the patient at significant risk if	
	he/she were to participate in the trial	
Interventions	First randomisation part A	Same interventions
	No additional treatment	
	Azithromycin	
	First randomisation part B	
	Convalescent plasma	
	Synthetic neutralising antibodies	
	Second randomisation	
	Tocilizumab	
Follow-up/	Ascertained at the time of death or discharge or at 28 days	Same follow-up and outcomes, with
outcomes	after randomisation (whichever is sooner):	addition of UKOSS COVID-19 case
	Vital status (alive/ dead, with date and presumed	number (for pregnancy and baby
	cause of death, if appropriate)	information) to allow later data linkage
	Hospitalisation status (inpatient/ discharged, with date	
	of discharge, if appropriate)	
	Use of ventilation (none/ previous/ ongoing, with days	
	of use and type, if appropriate)	
	Use of renal dialysis or haemofiltration (none/	
	previous/ ongoing)	
		Adaptions for breastfeeding
		The same interventions should be used
		UKOSS COVID-19 case number added if
		available.

Frequently asked questions

 Are the drugs safe in pregnancy? The pregnancy leads for the trial have reviewed the safety literature (Annex A), and experience around using these drugs for other conditions, and consider that participation in the trial is reasonable for pregnant and breastfeeding women. The regulators (MHRA and HRA) have agreed to the inclusion of pregnant women.

Eligibility = same



2.1 Eligibility

Patients are eligible for the study if all of the following are true:

- (i) Hospitalised
- (ii) SARS-CoV-2 infection (clinically suspected¹ or laboratory confirmed)
- (iii) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial

• No criterion for 'requiring oxygen'

Offer the RECOVERY trial if...




- Are you uncertain about the benefits of treatment or not for this woman, and whether it might 'treat' or prevent deterioration?
- If you are uncertain, then provide the trial information to the woman, offer the trial and make a shared decision.
- For any woman reportable to UKOSS, ask yourself whether you can offer her participation in RECOVERY

Interventions = the same



Current trial design





Use of drugs in pregnancy

RECOVERY Randomised Evaluation of COVID-19 Therapy

Azithromycin

Azithromycin is used in pregnancy to treat genital Chlamydia trachomatis infection, with a Cochrane systematic review and meta-analysis reporting fewer gastrointestinal side-effects compared to erythromycin, and inconsistent results on risk of preterm birth, preterm rupture of membranes, perinatal mortality and low birthweight, confounded by the indication for treatment.[1] A recent systematic review and meta-analysis of all macrolide antibiotics acknowledges potential bias in child outcome reports due to treatment indication.[2] The UK Teratology Information Service monograph concludes that there is no definitive evidence linking azithromycin with increased risk of miscarriage or congenital malformations (<u>https://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-MACROLIDES-IN-PREGNANCY/</u>). Azithromycin is detected in only low levels in breastmilk and is not expected to cause adverse events in breastfed infants (reviewed in Lactmed database: <u>www.ncbi.nlm.nih.gov/books/NBK501200/</u>). Azithromycin has also been used in several trials in preterm infants as a prophylactic treatment to prevent bronchopulmonary dysplasia.[3]

Convalescent plasma (prepared with Dr Sue Pavord, Consultant Haematologist)

Convalescent plasma is plasma from people who had confirmed COVID-19 (SARS-Cov-2) infection, and have now recovered and been free of the infection for 28 days. The plasma contains antibodies that their immune systems have produced in fighting the virus. It is hoped that giving this plasma will help speed up recovery of a patient with active infection and improve their chances of survival. Plasma is already used as a treatment in pregnant patients who are bleeding,[4] or have particular blood conditions.[5, 6] The plasma being used in this trial is from a selected donor and hopefully contains anti-SARS-Cov-2 antibodies, but is otherwise no different. Plasma infusions can occasionally cause side effects. Mostly this is a rise in temperature, itching or a rash, and in very extreme cases, anaphylaxis. Other potential complications include breathlessness and changes in blood pressure. Monitoring of pulse and blood pressure takes place before and after the infusion. There is no risk of miscarriage or fetal loss, preterm birth, preterm rupture of membranes, perinatal mortality or low birthweight, from plasma transfusions and there are no concerns with breast feeding.

Monoclonal antibodies (prepared with Dr Ken Hodson, Medical Director, UK TIS)

Monoclonal antibodies have been used as therapeutic agents in pregnancy over recent years, for a variety of conditions. Human monoclonal antibodies in use in pregnancy include anti-TNF agents, such as adalimumab, indicated for a variety of chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Data have recently accumulated from a variety of cohort and registry studies indicating that such exposure in pregnancy was not associated with an increased risk for adverse pregnancy outcomes, when compared to unexposed pregnancies with the same underlying medical diseases.[7] This is supported by a consensus report on immunosuppressives and biologics during pregnancy and lactation, confirming no evidence of elevated adverse pregnancy outcomes or malformation risks.[8] Some monoclonal antibodies are transported across the placenta (and may also enter breast milk) but as REGN10933 and REGN10987 do not have any human targets such exposure should not be associated with risk of harm. Pregnant women, just like other patients with COVID-19, are at significant risk from the infection itself (particularly those in the third trimester.[9, 10] All pregnant women in RECOVERY are entered into the UK Obstetric Surveillance System which follows all pregnancies to their conclusion.[10] Given the early safety experience with REGN10933+REGN10987 it would appear

RECOVERY information for pregnant patients V7.0 2020-10-05 Page 2 of 3

Follow-up = the same, + linkage



Q



Nuffield Department of POPULATION HEALTH



Contact About Us Research Public Involvement What's New Privacy Notice You are here: UKOSS / Current Surveillance / COVID-19 in Pregnancy

COVID-19 in Pregnancy

UK Obstetric Surveillance System

Search (e.g. Randomisation)

Key points

- Covid-19 is an infectious disease caused by a new strain of coronavirus.
- Covid-19 had not been detected in humans before the outbreak in December 2019.
- As the virus is new, little is known about its effect on certain groups of people, including pregnant women.

Surveillance period

1st March 2020 – 31st March 2021

Background

On this page

- Key points
- Surveillance period
- Background
- Objective
- Research questions
- Case definition
- Funding
- Ethics committee approval
- Study registration
- Lead investigator
- Download the Data Collection Form (DCF)
- References

Update on progress



- 160 pregnancy leads identified, supported by research midwives
- Midwife champions on board
- 30 antenatal women recruited and more postpartum women

Gestation at symptom onset

UK Ob



bstetric Sur	DSS rveillance System	OPEN ACCESS		RESEARCH tcomes of pregnant women admitted to d SARS-CoV-2 infection in UK: national ort study			
	Number of women (%						
	<22 weeks			22 (5)	22 (5)		
	22-	-27 wee	ks	60 (14)	60 (14)		
	28-3	6 weeks	5	170 (40)	170 (40)		
	37 or more weeks			172 (40)			
	Mi	ssing		3			





Outcomes for women **updated 07/10/20



Cobstetric Surveillance System	Number of women (%) (N=427)
Required critical care	41 (10)
Required ECMO	4 (1)
SARS-CoV-2 pneumonia on imaging	101 (24)
Final outcome	
Died	5 (1)
Discharged well	418 (98)
Missing	4 (1)

Maternal mortality rate 5.8 (95% CI 1.9 to 13.5) per 100,000 maternities



Pregnancy and infant outcomes*



		Number of women (%) (N=427)
JNUSS	Ongoing pregnancy/pregnancy outcome unknown	24 (6)
Obstetric Surveillance Syst	em Pregnancy completed	403 (94)
	Pregnancy loss	4 (1)
	Stillbirth	3 (1)
	Live birth	396 (98) (7 twin pregnancies)
	Neonatal death	2 (1)
	Gestation at birth (weeks)	
	22-31	25 (6)
	32-36	55 (14)
	37 or more	315 (79)
	Unknown	4 (1)
	Mode of birth	
	Caesarean – maternal indication due to SARS-CoV-2	43 (11)
	Caesarean – other indication	164 (41)
	Vaginal	192 (48)
	Pre-eclampsia	10 (2)

* Updated 07/10/2020



Infant outcomes (live born infants)

Positive test \geq 12 hrs of age





Live born infants of women with Sars-CoV-2 (N=401) Number (%) **NICU Admission** 85 (21) **Positive SARS-CoV-2 test** No 388 (97) 6 (1) Only 1 (0.2%) had Positive test <12 hrs of age confirmed infection



7 (2)

ICNARC data (critical care)





Napier House 24 High Holborn London WC1V 6AZ email: COVID-19@icnarc.org www.icnarc.org

ICNARC report on COVID-19 in critical care:

England, Wales and Northern Ireland

23 October 2020

Table 2. Patient characteristics: medical history

	Patients with co	Patients with confirmed COVID-19		
Medical history	Admitted from 1 Sep (N=1761)	Admitted up to 31 Aug (N=10,904)		
Dependency prior to admission to acute hospital, n (%) [N=1567]				
Able to live without assistance in daily activities	1391 (88.8)	9653 (89.4)		
Some assistance with daily activities	174 (11.1)	1109 (10.3)		
Total assistance with all daily activities	2 (0.1)	40 (0.4)		
Very severe comorbidities *, n (%) [N=1600]				
Cardiovascular	16 (1.0)	70 (0.6)		
Respiratory	24 (1.5)	126 (1.2)		
Renal	24 (1.5)	186 (1.7)		
Liver	9 (0.6)	50 (0.5)		
Metastatic disease	11 (0.7)	59 (0.5)		
Haematological malignancy	27 (1.7)	212 (2.0)		
Immunocompromise	79 (4.9)	386 (3.6)		
CPR within previous 24h, n (%) [N=1618]				
In the community	8 (0.5)	50 (0.5)		
In hospital	12 (0.7)	76 (0.7)		
Prior hospital length of stay [N=1726]				
Mean (SD)	2.3 (4.5)	2.5 (6.2)		
Median (IQR)	1 (0, 3)	1 (0, 3)		
Currently or recently pregnant, n (% of females aged 16-49) [N=144]				
Currently pregnant	15 (10.4)	29 (3.7)		
Recently pregnant (within 6 weeks)	6 (4.2)	41 (5.2)		
Not known to be pregnant	123 (85.4)	718 (91.1)		

Recognition of severe illness

RECEVERY Randomised Evaluation of COVID-19 Therapy

<text><text><text><text><text><text><text><text><text>

A woman in her third trimester of pregnancy presented to the Emergency Department with a one week history of symptoms of COVID-19. Her observations were documented using a National Early Warning Score (NEWS) and not a modified early obstetric warning score (MEOWS). She had a respiratory rate of 36 but this was not recognised as significant. Her first review by a member of obstetric staff was eleven hours after she attended, when a junior obstetrician identified no obstetric concerns. She deteriorated a few days later and was documented to need high dependency or intensive care but no beds were available in either high dependency or intensive care areas. Her care was discussed with a consultant obstetrician at the time of her deterioration and a decision made for a caesarean birth. Following the birth, it was again noted that no beds were available and she was transferred back to a general ward where she deteriorated. She was intubated and transferred to the intensive care unit but her condition continued to worsen and she died a few days later.

Ensure all pregnant or post-partum women with COVID-19 receive multidisciplinary team care and obstetric leadership with daily review. This is essential in order to ensure timely recognition of deterioration, early assessment of the need for iatrogenic birth to help respiratory function and identification of postnatal complications.







- Anticipate ongoing new cases over coming weeks
- Check team (and new doctors) are ready for recruitment
- Think through pathways for notification of cases
- Use UKOSS as prompt to help (and for outcomes)
- Link with main RECOVERY research teams
- Embed into usual practice
- Offer trial



